Science 11 November 1994: Vol. 266. no. 5187, pp. 1024 - 1027 DOI: 10.1126/science.7973652

Prev | Table of Contents | Next

Articles

Novel Ring Structure in the gp41 Trimer of Human Immunodeficiency Virus Type 1 That Modulates Sensitivity and Resistance to Broadly Neutralizing Antibodies.

S. M. O'Rourke, B. Schweighardt, W. G. Scott, T. Wrin, D. P. A. J. Fonseca, F. Sinangil, and P. W. Berman (2009)
J. Virol. 83, 7728-7738
 |  Abstract »  |  Full Text »  |  PDF »

Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm.

M. D. Simek, W. Rida, F. H. Priddy, P. Pung, E. Carrow, D. S. Laufer, J. K. Lehrman, M. Boaz, T. Tarragona-Fiol, G. Miiro, et al. (2009)
J. Virol. 83, 7337-7348
 |  Abstract »  |  Full Text »  |  PDF »

Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface.

L. Song, Z.-Y. J. Sun, K. E. Coleman, M. B. Zwick, J. S. Gach, J.-h. Wang, E. L. Reinherz, G. Wagner, and M. Kim (2009)
PNAS 106, 9057-9062
 |  Abstract »  |  Full Text »  |  PDF »

Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain.

L. Wu, T. Zhou, Z.-y. Yang, K. Svehla, S. O'Dell, M. K. Louder, L. Xu, J. R. Mascola, D. R. Burton, J. A. Hoxie, et al. (2009)
J. Virol. 83, 5077-5086
 |  Abstract »  |  Full Text »  |  PDF »

Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.

J. S. Klein, P. N. P. Gnanapragasam, R. P. Galimidi, C. P. Foglesong, A. P. West Jr, and P. J. Bjorkman (2009)
PNAS 106, 7385-7390
 |  Abstract »  |  Full Text »  |  PDF »

Detection of typical and atypical bovine spongiform encephalopathy and scrapie prion strains by prion protein motif-grafted antibodies.

F. Martucci, P. Acutis, M. Mazza, S. Nodari, S. Colussi, C. Corona, S. Barocci, A. Gabrielli, M. Caramelli, C. Casalone, et al. (2009)
J. Gen. Virol. 90, 1048-1053
 |  Abstract »  |  Full Text »  |  PDF »

Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.

Y. Guan, M. M. Sajadi, R. Kamin-Lewis, T. R. Fouts, A. Dimitrov, Z. Zhang, R. R. Redfield, A. L. DeVico, R. C. Gallo, and G. K. Lewis (2009)
PNAS 106, 3952-3957
 |  Abstract »  |  Full Text »  |  PDF »

The Human Immunodeficiency Virus Type 1 Envelope Spike of Primary Viruses Can Suppress Antibody Access to Variable Regions.

R. Pantophlet, M. Wang, R. O. Aguilar-Sino, and D. R. Burton (2009)
J. Virol. 83, 1649-1659
 |  Abstract »  |  Full Text »  |  PDF »

Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes..

X. M. Luo, E. Maarschalk, R. M. O'Connell, P. Wang, L. Yang, and D. Baltimore (2009)
Blood 113, 1422-1431
 |  Abstract »  |  Full Text »  |  PDF »

Continuous Viral Escape and Selection by Autologous Neutralizing Antibodies in Drug-Naive Human Immunodeficiency Virus Controllers.

M. Mahalanabis, P. Jayaraman, T. Miura, F. Pereyra, E. M. Chester, B. Richardson, B. Walker, and N. L. Haigwood (2009)
J. Virol. 83, 662-672
 |  Abstract »  |  Full Text »  |  PDF »

Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals.

Y. Li, K. Svehla, M. K. Louder, D. Wycuff, S. Phogat, M. Tang, S. A. Migueles, X. Wu, A. Phogat, G. M. Shaw, et al. (2009)
J. Virol. 83, 1045-1059
 |  Abstract »  |  Full Text »  |  PDF »

Optimization of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins with V1/V2 Deleted, Using Virus Evolution.

I. Bontjer, A. Land, D. Eggink, E. Verkade, K. Tuin, C. Baldwin, G. Pollakis, W. A. Paxton, I. Braakman, B. Berkhout, et al. (2009)
J. Virol. 83, 368-383
 |  Abstract »  |  Full Text »  |  PDF »

Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120.

A. Forsman, E. Beirnaert, M. M. I. Aasa-Chapman, B. Hoorelbeke, K. Hijazi, W. Koh, V. Tack, A. Szynol, C. Kelly, A. McKnight, et al. (2008)
J. Virol. 82, 12069-12081
 |  Abstract »  |  Full Text »  |  PDF »

Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C.

J. M. Binley, E. A. Lybarger, E. T. Crooks, M. S. Seaman, E. Gray, K. L. Davis, J. M. Decker, D. Wycuff, L. Harris, N. Hawkins, et al. (2008)
J. Virol. 82, 11651-11668
 |  Abstract »  |  Full Text »  |  PDF »

Importance of the V1/V2 Loop Region of Simian-Human Immunodeficiency Virus Envelope Glycoprotein gp120 in Determining the Strain Specificity of the Neutralizing Antibody Response.

M. E. Laird, T. Igarashi, M. A. Martin, and R. C. Desrosiers (2008)
J. Virol. 82, 11054-11065
 |  Abstract »  |  Full Text »  |  PDF »

Scrapie-Induced Defects in Learning and Memory of Transgenic Mice Expressing Anchorless Prion Protein Are Associated with Alterations in the Gamma Aminobutyric Acid-Ergic Pathway.

M. J. Trifilo, M. Sanchez-Alavez, L. Solforosi, J. Bernard-Trifilo, S. Kunz, D. McGavern, and M. B. A. Oldstone (2008)
J. Virol. 82, 9890-9899
 |  Abstract »  |  Full Text »  |  PDF »

Virological Consequences of Early Events following Cell-Cell Contact between Human Immunodeficiency Virus Type 1-Infected and Uninfected CD4+ Cells.

E. Ruggiero, R. Bona, C. Muratori, and M. Federico (2008)
J. Virol. 82, 7773-7789
 |  Abstract »  |  Full Text »  |  PDF »

R5X4 Viruses Are Evolutionary, Functional, and Antigenic Intermediates in the Pathway of a Simian-Human Immunodeficiency Virus Coreceptor Switch.

S. Tasca, S.-H. Ho, and C. Cheng-Mayer (2008)
J. Virol. 82, 7089-7099
 |  Abstract »  |  Full Text »  |  PDF »

Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody That Recognizes a Novel Conformational Epitope on gp41 and Lacks Reactivity against Self-Antigens.

M.-Y. Zhang, B. K. Vu, A. Choudhary, H. Lu, M. Humbert, H. Ong, M. Alam, R. M. Ruprecht, G. Quinnan, S. Jiang, et al. (2008)
J. Virol. 82, 6869-6879
 |  Abstract »  |  Full Text »  |  PDF »

A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120.

R. D. Astronomo, H.-K. Lee, C. N. Scanlan, R. Pantophlet, C.-Y. Huang, I. A. Wilson, O. Blixt, R. A. Dwek, C.-H. Wong, and D. R. Burton (2008)
J. Virol. 82, 6359-6368
 |  Abstract »  |  Full Text »  |  PDF »

Cost-effective production of a vaginal protein microbicide to prevent HIV transmission.

K. Ramessar, T. Rademacher, M. Sack, J. Stadlmann, D. Platis, G. Stiegler, N. Labrou, F. Altmann, J. Ma, E. Stoger, et al. (2008)
PNAS 105, 3727-3732
 |  Abstract »  |  Full Text »  |  PDF »

A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.

G. Frey, H. Peng, S. Rits-Volloch, M. Morelli, Y. Cheng, and B. Chen (2008)
PNAS 105, 3739-3744
 |  Abstract »  |  Full Text »  |  PDF »

The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design.

M. Montero, N. E. van Houten, X. Wang, and J. K. Scott (2008)
Microbiol. Mol. Biol. Rev. 72, 54-84
 |  Abstract »  |  Full Text »  |  PDF »

Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody Responses.

Y. Li, B. Cleveland, I. Klots, B. Travis, B. A. Richardson, D. Anderson, D. Montefiori, P. Polacino, and S.-L. Hu (2008)
J. Virol. 82, 638-651
 |  Abstract »  |  Full Text »  |  PDF »

Mutations in Envelope gp120 Can Impact Proteolytic Processing of the gp160 Precursor and Thereby Affect Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Pseudoviruses.

W. M. Blay, T. Kasprzyk, L. Misher, B. A. Richardson, and N. L. Haigwood (2007)
J. Virol. 81, 13037-13049
 |  Abstract »  |  Full Text »  |  PDF »

A Monoclonal Fab Derived from a Human Nonimmune Phage Library Reveals a New Epitope on gp41 and Neutralizes Diverse Human Immunodeficiency Virus Type 1 Strains.

E. Gustchina, J. M. Louis, S. N. Lam, C. A. Bewley, and G. M. Clore (2007)
J. Virol. 81, 12946-12953
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of HIV-1 Infectivity and Epithelial Cell Transfer by Human Monoclonal IgG and IgA Antibodies Carrying the b12 V Region.

N. J. Mantis, J. Palaia, A. J. Hessell, S. Mehta, Z. Zhu, B. Corthesy, M. R. Neutra, D. R. Burton, and E. N. Janoff (2007)
J. Immunol. 179, 3144-3152
 |  Abstract »  |  Full Text »  |  PDF »

Susceptibility of Recently Transmitted Subtype B Human Immunodeficiency Virus Type 1 Variants to Broadly Neutralizing Antibodies.

E. D. Quakkelaar, F. P. J. van Alphen, B. D. M. Boeser-Nunnink, A. C. van Nuenen, R. Pantophlet, and H. Schuitemaker (2007)
J. Virol. 81, 8533-8542
 |  Abstract »  |  Full Text »  |  PDF »

In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10.

A. Manrique, P. Rusert, B. Joos, M. Fischer, H. Kuster, C. Leemann, B. Niederost, R. Weber, G. Stiegler, H. Katinger, et al. (2007)
J. Virol. 81, 8793-8808
 |  Abstract »  |  Full Text »  |  PDF »

Conserved Changes in Envelope Function during Human Immunodeficiency Virus Type 1 Coreceptor Switching.

C. Pastore, R. Nedellec, A. Ramos, O. Hartley, J. L. Miamidian, J. D. Reeves, and D. E. Mosier (2007)
J. Virol. 81, 8165-8179
 |  Abstract »  |  Full Text »  |  PDF »

Macaques Infected with a CCR5-Tropic Simian/Human Immunodeficiency Virus (SHIV) Develop Broadly Reactive Anti-HIV Neutralizing Antibodies.

Z. Kraft, N. R. Derby, R. A. McCaffrey, R. Niec, W. M. Blay, N. L. Haigwood, E. Moysi, C. J. Saunders, T. Wrin, C. J. Petropoulos, et al. (2007)
J. Virol. 81, 6402-6411
 |  Abstract »  |  Full Text »  |  PDF »

Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors.

A. K. Dhillon, H. Donners, R. Pantophlet, W. E. Johnson, J. M. Decker, G. M. Shaw, F.-H. Lee, D. D. Richman, R. W. Doms, G. Vanham, et al. (2007)
J. Virol. 81, 6548-6562
 |  Abstract »  |  Full Text »  |  PDF »

Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity.

B. Dey, M. Pancera, K. Svehla, Y. Shu, S.-H. Xiang, J. Vainshtein, Y. Li, J. Sodroski, P. D. Kwong, J. R. Mascola, et al. (2007)
J. Virol. 81, 5579-5593
 |  Abstract »  |  Full Text »  |  PDF »

Antigenic and Immunogenic Study of Membrane-Proximal External Region-Grafted gp120 Antigens by a DNA Prime-Protein Boost Immunization Strategy.

M. Law, R. M. F. Cardoso, I. A. Wilson, and D. R. Burton (2007)
J. Virol. 81, 4272-4285
 |  Abstract »  |  Full Text »  |  PDF »

An Affinity-Enhanced Neutralizing Antibody against the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 gp41 Recognizes an Epitope between Those of 2F5 and 4E10.

J. D. Nelson, F. M. Brunel, R. Jensen, E. T. Crooks, R. M. F. Cardoso, M. Wang, A. Hessell, I. A. Wilson, J. M. Binley, P. E. Dawson, et al. (2007)
J. Virol. 81, 4033-4043
 |  Abstract »  |  Full Text »  |  PDF »

Time Frames for Neutralization during the Human Immunodeficiency Virus Type 1 Entry Phase, as Monitored in Synchronously Infected Cell Cultures.

H. Haim, I. Steiner, and A. Panet (2007)
J. Virol. 81, 3525-3534
 |  Abstract »  |  Full Text »  |  PDF »

Type-Specific Epitopes Targeted by Monoclonal Antibodies with Exceptionally Potent Neutralizing Activities for Selected Strains of Human Immunodeficiency Virus Type 1 Map to a Common Region of the V2 Domain of gp120 and Differ Only at Single Positions from the Clade B Consensus Sequence.

W. J. Honnen, C. Krachmarov, S. C. Kayman, M. K. Gorny, S. Zolla-Pazner, and A. Pinter (2007)
J. Virol. 81, 1424-1432
 |  Abstract »  |  Full Text »  |  PDF »

Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage.

D.R. Bowley, A.F. Labrijn, M.B. Zwick, and D.R. Burton (2007)
Protein Eng. Des. Sel. 20, 81-90
 |  Abstract »  |  Full Text »  |  PDF »

Stoichiometry of Murine Leukemia Virus Envelope Protein-Mediated Fusion and Its Neutralization.

W. Ou and J. Silver (2006)
J. Virol. 80, 11982-11990
 |  Abstract »  |  Full Text »  |  PDF »

Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa.

M. Li, J. F. Salazar-Gonzalez, C. A. Derdeyn, L. Morris, C. Williamson, J. E. Robinson, J. M. Decker, Y. Li, M. G. Salazar, V. R. Polonis, et al. (2006)
J. Virol. 80, 11776-11790
 |  Abstract »  |  Full Text »  |  PDF »

Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV-1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection..

N. R. Derby, Z. Kraft, E. Kan, E. T. Crooks, S. W. Barnett, I. K. Srivastava, J. M. Binley, and L. Stamatatos (2006)
J. Virol. 80, 8745-8762
 |  Abstract »  |  Full Text »  |  PDF »

Histatin 5-derived Peptide with improved fungicidal properties enhances human immunodeficiency virus type 1 replication by promoting viral entry..

F. Groot, R. W. Sanders, O. ter Brake, K. Nazmi, E. C. I. Veerman, J. G. M. Bolscher, and B. Berkhout (2006)
J. Virol. 80, 9236-9243
 |  Abstract »  |  Full Text »  |  PDF »

Computational prediction of the cross-reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV-1 gp120.

E. M. Bublil, S. Yeger-Azuz, and J. M. Gershoni (2006)
FASEB J 20, 1762-1774
 |  Abstract »  |  Full Text »  |  PDF »

Cross-Clade Neutralizing Activity of Human Anti-V3 Monoclonal Antibodies Derived from the Cells of Individuals Infected with Non-B Clades of Human Immunodeficiency Virus Type 1.

M. K. Gorny, C. Williams, B. Volsky, K. Revesz, X.-H. Wang, S. Burda, T. Kimura, F. A. J. Konings, A. Nadas, C. A. Anyangwe, et al. (2006)
J. Virol. 80, 6865-6872
 |  Abstract »  |  Full Text »  |  PDF »

Factors Determining the Breadth and Potency of Neutralization by V3-Specific Human Monoclonal Antibodies Derived from Subjects Infected with Clade A or Clade B Strains of Human Immunodeficiency Virus Type 1.

C. P. Krachmarov, W. J. Honnen, S. C. Kayman, M. K. Gorny, S. Zolla-Pazner, and A. Pinter (2006)
J. Virol. 80, 7127-7135
 |  Abstract »  |  Full Text »  |  PDF »

Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants..

R. Dickover, E. Garratty, K. Yusim, C. Miller, B. Korber, and Y. Bryson (2006)
J. Virol. 80, 6525-6533
 |  Abstract »  |  Full Text »  |  PDF »

Anti-V3 Humanized Antibody KD-247 Effectively Suppresses Ex Vivo Generation of Human Immunodeficiency Virus Type 1 and Affords Sterile Protection of Monkeys against a Heterologous Simian/Human Immunodeficiency Virus Infection..

Y. Eda, T. Murakami, Y. Ami, T. Nakasone, M. Takizawa, K. Someya, M. Kaizu, Y. Izumi, N. Yoshino, S. Matsushita, et al. (2006)
J. Virol. 80, 5563-5570
 |  Abstract »  |  Full Text »  |  PDF »

Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1.

P. L. Moore, E. T. Crooks, L. Porter, P. Zhu, C. S. Cayanan, H. Grise, P. Corcoran, M. B. Zwick, M. Franti, L. Morris, et al. (2006)
J. Virol. 80, 2515-2528
 |  Abstract »  |  Full Text »  |  PDF »

Effect of Epitope Position on Neutralization by Anti-Human Immunodeficiency Virus Monoclonal Antibody 2F5.

W. Ou, N. Lu, S. S. Yu, and J. Silver (2006)
J. Virol. 80, 2539-2547
 |  Abstract »  |  Full Text »  |  PDF »

Structure-Function Analysis of the Epitope for 4E10, a Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody.

F. M. Brunel, M. B. Zwick, R. M. F. Cardoso, J. D. Nelson, I. A. Wilson, D. R. Burton, and P. E. Dawson (2006)
J. Virol. 80, 1680-1687
 |  Abstract »  |  Full Text »  |  PDF »

Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques.

W.M. Blay, S. Gnanakaran, B. Foley, N. A. Doria-Rose, B. T. Korber, and N. L. Haigwood (2006)
J. Virol. 80, 999-1014
 |  Abstract »  |  Full Text »  |  PDF »

Human Recombinant Antimannan Immunoglobulin G1 Antibody Confers Resistance to Hematogenously Disseminated Candidiasis in Mice.

M. X. Zhang, M. C. Bohlman, C. Itatani, D. R. Burton, P. W. H. I. Parren, S. C. St. Jeor, and T. R. Kozel (2006)
Infect. Immun. 74, 362-369
 |  Abstract »  |  Full Text »  |  PDF »

A Highly Conserved Arginine in gp120 Governs HIV-1 Binding to Both Syndecans and CCR5 via Sulfated Motifs.

A. de Parseval, M. D. Bobardt, A. Chatterji, U. Chatterji, J. H. Elder, G. David, S. Zolla-Pazner, M. Farzan, T.-H. Lee, and P. A. Gallay (2005)
J. Biol. Chem. 280, 39493-39504
 |  Abstract »  |  Full Text »  |  PDF »

Comparing Antigenicity and Immunogenicity of Engineered gp120.

S. Selvarajah, B. Puffer, R. Pantophlet, M. Law, R. W. Doms, and D. R. Burton (2005)
J. Virol. 79, 12148-12163
 |  Abstract »  |  Full Text »  |  PDF »

Inactivation of Retroviruses with Preservation of Structural Integrity by Targeting the Hydrophobic Domain of the Viral Envelope.

Y. Raviv, M. Viard, J. W Bess Jr., E. Chertova, and R. Blumenthal (2005)
J. Virol. 79, 12394-12400
 |  Abstract »  |  Full Text »  |  PDF »

Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies.

M. Li, F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, et al. (2005)
J. Virol. 79, 10108-10125
 |  Abstract »  |  Full Text »  |  PDF »

Soluble Mimetics of Human Immunodeficiency Virus Type 1 Viral Spikes Produced by Replacement of the Native Trimerization Domain with a Heterologous Trimerization Motif: Characterization and Ligand Binding Analysis.

M. Pancera, J. Lebowitz, A. Schon, P. Zhu, E. Freire, P. D. Kwong, K. H. Roux, J. Sodroski, and R. Wyatt (2005)
J. Virol. 79, 9954-9969
 |  Abstract »  |  Full Text »  |  PDF »

The V1, V2, and V3 Regions of the Human Immunodeficiency Virus Type 1 Envelope Differentially Affect the Viral Phenotype in an Isolate-Dependent Manner.

C. J. Saunders, R. A. McCaffrey, I. Zharkikh, Z. Kraft, S. E. Malenbaum, B. Burke, C. Cheng-Mayer, and L. Stamatatos (2005)
J. Virol. 79, 9069-9080
 |  Abstract »  |  Full Text »  |  PDF »

Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors.

P. Rusert, H. Kuster, B. Joos, B. Misselwitz, C. Gujer, C. Leemann, M. Fischer, G. Stiegler, H. Katinger, W. C. Olson, et al. (2005)
J. Virol. 79, 8454-8469
 |  Abstract »  |  Full Text »  |  PDF »

Interaction with CD4 and Antibodies to CD4-Induced Epitopes of the Envelope gp120 from a Microglial Cell-Adapted Human Immunodeficiency Virus Type 1 Isolate.

J. Martin-Garcia, S. Cocklin, I. M. Chaiken, and F. Gonzalez-Scarano (2005)
J. Virol. 79, 6703-6713
 |  Abstract »  |  Full Text »  |  PDF »

Enfuvirtide Resistance Mutations: Impact on Human Immunodeficiency Virus Envelope Function, Entry Inhibitor Sensitivity, and Virus Neutralization.

J. D. Reeves, F.-H. Lee, J. L. Miamidian, C. B. Jabara, M. M. Juntilla, and R. W. Doms (2005)
J. Virol. 79, 4991-4999
 |  Abstract »  |  Full Text »  |  PDF »

Identification of a New Quaternary Neutralizing Epitope on Human Immunodeficiency Virus Type 1 Virus Particles.

M. K. Gorny, L. Stamatatos, B. Volsky, K. Revesz, C. Williams, X.-H. Wang, S. Cohen, R. Staudinger, and S. Zolla-Pazner (2005)
J. Virol. 79, 5232-5237
 |  Abstract »  |  Full Text »  |  PDF »

Stoichiometry of Antibody Neutralization of Human Immunodeficiency Virus Type 1.

X. Yang, S. Kurteva, S. Lee, and J. Sodroski (2005)
J. Virol. 79, 3500-3508
 |  Abstract »  |  Full Text »  |  PDF »

Antibody Neutralization Escape Mediated by Point Mutations in the Intracytoplasmic Tail of Human Immunodeficiency Virus Type 1 gp41.

V. Kalia, S. Sarkar, P. Gupta, and R. C. Montelaro (2005)
J. Virol. 79, 2097-2107
 |  Abstract »  |  Full Text »  |  PDF »

Characterization of gp120 and Its Single-Chain Derivatives, gp120-CD4D12 and gp120-M9: Implications for Targeting the CD4i Epitope in Human Immunodeficiency Virus Vaccine Design.

R. Varadarajan, D. Sharma, K. Chakraborty, M. Patel, M. Citron, P. Sinha, R. Yadav, U. Rashid, S. Kennedy, D. Eckert, et al. (2005)
J. Virol. 79, 1713-1723
 |  Abstract »  |  Full Text »  |  PDF »

Antibodies That Are Cross-Reactive for Human Immunodeficiency Virus Type 1 Clade A and Clade B V3 Domains Are Common in Patient Sera from Cameroon, but Their Neutralization Activity Is Usually Restricted by Epitope Masking.

C. Krachmarov, A. Pinter, W. J. Honnen, M. K. Gorny, P. N. Nyambi, S. Zolla-Pazner, and S. C. Kayman (2005)
J. Virol. 79, 780-790
 |  Abstract »  |  Full Text »  |  PDF »

Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Antibodies 2F5 and 4E10 Require Surprisingly Few Crucial Residues in the Membrane-Proximal External Region of Glycoprotein gp41 To Neutralize HIV-1.

M. B. Zwick, R. Jensen, S. Church, M. Wang, G. Stiegler, R. Kunert, H. Katinger, and D. R. Burton (2005)
J. Virol. 79, 1252-1261
 |  Abstract »  |  Full Text »  |  PDF »

Part of the C-terminal tail of the envelope gp41 transmembrane glycoprotein of human immunodeficiency virus type 1 is exposed on the surface of infected cells and is involved in virus-mediated cell fusion.

L. Cheung, L. McLain, M. J. Hollier, S. A. Reading, and N. J. Dimmock (2005)
J. Gen. Virol. 86, 131-138
 |  Abstract »  |  Full Text »  |  PDF »

Characterization of the Outer Domain of the gp120 Glycoprotein from Human Immunodeficiency Virus Type 1.

X. Yang, V. Tomov, S. Kurteva, L. Wang, X. Ren, M. K. Gorny, S. Zolla-Pazner, and J. Sodroski (2004)
J. Virol. 78, 12975-12986
 |  Abstract »  |  Full Text »  |  PDF »

Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies.

J. M. Binley, T. Wrin, B. Korber, M. B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, et al. (2004)
J. Virol. 78, 13232-13252
 |  Abstract »  |  Full Text »  |  PDF »

Evolutionary Dynamics of the Glycan Shield of the Human Immunodeficiency Virus Envelope during Natural Infection and Implications for Exposure of the 2G12 Epitope.

L. Dacheux, A. Moreau, Y. Ataman-Onal, F. Biron, B. Verrier, and F. Barin (2004)
J. Virol. 78, 12625-12637
 |  Abstract »  |  Full Text »  |  PDF »

Involvement of Fc{gamma}R I (CD64) in the Mechanism of HIV-1 Inhibition by Polyclonal IgG Purified from Infected Patients in Cultured Monocyte-Derived Macrophages.

V. Holl, S. Hemmerter, R. Burrer, S. Schmidt, A. Bohbot, A.-M. Aubertin, and C. Moog (2004)
J. Immunol. 173, 6274-6283
 |  Abstract »  |  Full Text »  |  PDF »

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12.

C. Armbruster, G. M. Stiegler, B. A. Vcelar, W. Jager, U. Koller, R. Jilch, C. G. Ammann, M. Pruenster, H. Stoiber, and H. W. D. Katinger (2004)
J. Antimicrob. Chemother. 54, 915-920
 |  Abstract »  |  Full Text »  |  PDF »

A Nonneutralizing Anti-HIV-1 Antibody Turns into a Neutralizing Antibody When Expressed on the Surface of HIV-1-Susceptible Cells: A New Way to Fight HIV.

S.-J. Lee, L. Garza, J. Yao, A. L. Notkins, and P. Zhou (2004)
J. Immunol. 173, 4618-4626
 |  Abstract »  |  Full Text »  |  PDF »

Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.

R. Pantophlet, I.A. Wilson, and D.R. Burton (2004)
Protein Eng. Des. Sel. 17, 749-758
 |  Abstract »  |  Full Text »  |  PDF »

Naturally Occurring Proteolytic Antibodies: SELECTIVE IMMUNOGLOBULIN M-CATALYZED HYDROLYSIS OF HIV gp120.

S. Paul, S. Karle, S. Planque, H. Taguchi, M. Salas, Y. Nishiyama, B. Handy, R. Hunter, A. Edmundson, and C. Hanson (2004)
J. Biol. Chem. 279, 39611-39619
 |  Abstract »  |  Full Text »  |  PDF »

Identification and Characterization of a New Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody.

M.-Y. Zhang, X. Xiao, I. A. Sidorov, V. Choudhry, F. Cham, P. F. Zhang, P. Bouma, M. Zwick, A. Choudhary, D. C. Montefiori, et al. (2004)
J. Virol. 78, 9233-9242
 |  Abstract »  |  Full Text »  |  PDF »

Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc.

G. Moroncini, N. Kanu, L. Solforosi, G. Abalos, G. C. Telling, M. Head, J. Ironside, J. P. Brockes, D. R. Burton, and R. A. Williamson (2004)
PNAS 101, 10404-10409
 |  Abstract »  |  Full Text »  |  PDF »

Passive Immunotherapy in Simian Immunodeficiency Virus-Infected Macaques Accelerates the Development of Neutralizing Antibodies.

N. L. Haigwood, D. C. Montefiori, W. F. Sutton, J. McClure, A. J. Watson, G. Voss, V. M. Hirsch, B. A. Richardson, N. L. Letvin, S.-L. Hu, et al. (2004)
J. Virol. 78, 5983-5995
 |  Abstract »  |  Full Text »  |  PDF »

The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection.

A. Pinter, W. J. Honnen, Y. He, M. K. Gorny, S. Zolla-Pazner, and S. C. Kayman (2004)
J. Virol. 78, 5205-5215
 |  Abstract »  |  Full Text »  |  PDF »

Identification of Chimpanzee Fab Fragments by Repertoire Cloning and Production of a Full-Length Humanized Immunoglobulin G1 Antibody That Is Highly Efficient for Neutralization of Dengue Type 4 Virus.

R. Men, T. Yamashiro, A. P. Goncalvez, C. Wernly, D. J. Schofield, S. U. Emerson, R. H. Purcell, and C.-J. Lai (2004)
J. Virol. 78, 4665-4674
 |  Abstract »  |  Full Text »  |  PDF »

Blockade of Attachment and Fusion Receptors Inhibits HIV-1 Infection of Human Cervical Tissue.

Q. Hu, I. Frank, V. Williams, J. J. Santos, P. Watts, G. E. Griffin, J. P. Moore, M. Pope, and R. J. Shattock (2004)
J. Exp. Med. 199, 1065-1075
 |  Abstract »  |  Full Text »  |  PDF »

N-Linked Glycosylation of the V3 Loop and the Immunologically Silent Face of gp120 Protects Human Immunodeficiency Virus Type 1 SF162 from Neutralization by Anti-gp120 and Anti-gp41 Antibodies.

R. A. McCaffrey, C. Saunders, M. Hensel, and L. Stamatatos (2004)
J. Virol. 78, 3279-3295
 |  Abstract »  |  Full Text »  |  PDF »

Covalently Linked Human Immunodeficiency Virus Type 1 gp120/gp41 Is Stably Anchored in Rhabdovirus Particles and Exposes Critical Neutralizing Epitopes.

P. M. McKenna, R. J. Pomerantz, B. Dietzschold, J. P. McGettigan, and M. J. Schnell (2003)
J. Virol. 77, 12782-12794
 |  Abstract »  |  Full Text »  |  PDF »

Specific CD4 down-modulating compounds with potent anti-HIV activity.

K. Vermeire and D. Schols (2003)
J. Leukoc. Biol. 74, 667-675
 |  Abstract »  |  Full Text »  |  PDF »

Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1.

A. F. Labrijn, P. Poignard, A. Raja, M. B. Zwick, K. Delgado, M. Franti, J. Binley, V. Vivona, C. Grundner, C.-C. Huang, et al. (2003)
J. Virol. 77, 10557-10565
 |  Abstract »  |  Full Text »  |  PDF »

Blocking the docking of HIV-1.

A. McKnight and R. A. Weiss (2003)
PNAS 100, 10581-10582
 |  Full Text »  |  PDF »

Envelope Variants from Women Recently Infected with Clade A Human Immunodeficiency Virus Type 1 Confer Distinct Phenotypes That Are Discerned by Competition and Neutralization Experiments.

S. L. Painter, R. Biek, D. C. Holley, and M. Poss (2003)
J. Virol. 77, 8448-8461
 |  Abstract »  |  Full Text »  |  PDF »

Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition.

D. A. Calarese, C. N. Scanlan, M. B. Zwick, S. Deechongkit, Y. Mimura, R. Kunert, P. Zhu, M. R. Wormald, R. L. Stanfield, K. H. Roux, et al. (2003)
Science 300, 2065-2071
 |  Abstract »  |  Full Text »  |  PDF »

A Novel Human Antibody against Human Immunodeficiency Virus Type 1 gp120 Is V1, V2, and V3 Loop Dependent and Helps Delimit the Epitope of the Broadly Neutralizing Antibody Immunoglobulin G1 b12.

M. B. Zwick, R. Kelleher, R. Jensen, A. F. Labrijn, M. Wang, G. V. Quinnan Jr., P. W. H. I. Parren, and D. R. Burton (2003)
J. Virol. 77, 6965-6978
 |  Abstract »  |  Full Text »  |  PDF »

Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions.

J. M. Binley, C. S. Cayanan, C. Wiley, N. Schulke, W. C. Olson, and D. R. Burton (2003)
J. Virol. 77, 5678-5684
 |  Abstract »  |  Full Text »  |  PDF »

Molecular Features of the Broadly Neutralizing Immunoglobulin G1 b12 Required for Recognition of Human Immunodeficiency Virus Type 1 gp120.

M. B. Zwick, P. W. H. I. Parren, E. O. Saphire, S. Church, M. Wang, J. K. Scott, P. E. Dawson, I. A. Wilson, and D. R. Burton (2003)
J. Virol. 77, 5863-5876
 |  Abstract »  |  Full Text »  |  PDF »

Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design.

R. Pantophlet, I. A. Wilson, and D. R. Burton (2003)
J. Virol. 77, 5889-5901
 |  Abstract »  |  Full Text »  |  PDF »

Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection.

G. Stiegler and H. Katinger (2003)
J. Antimicrob. Chemother. 51, 757-759
 |  Full Text »  |  PDF »

Viremia Control Despite Escape from a Rapid and Potent Autologous Neutralizing Antibody Response After Therapy Cessation in an HIV-1-Infected Individual.

D. C. Montefiori, M. Altfeld, P. K. Lee, M. Bilska, J. Zhou, M. N. Johnston, F. Gao, B. D. Walker, and E. S. Rosenberg (2003)
J. Immunol. 170, 3906-3914
 |  Abstract »  |  Full Text »  |  PDF »

A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion.

S. M. Cleveland, L. McLain, L. Cheung, T. D. Jones, M. Hollier, and N. J. Dimmock (2003)
J. Gen. Virol. 84, 591-602
 |  Abstract »  |  Full Text »  |  PDF »

Neutralization of Human Immunodeficiency Virus Type 1 by sCD4-17b, a Single-Chain Chimeric Protein, Based on Sequential Interaction of gp120 with CD4 and Coreceptor.

B. Dey, C. S. Del Castillo, and E. A. Berger (2003)
J. Virol. 77, 2859-2865
 |  Abstract »  |  Full Text »  |  PDF »

Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost.

L. Vinner, E. G.-T. Wee, S. Patel, S. Corbet, G. P. Gao, C. Nielsen, J. M. Wilson, H. C. J. Ertl, T. Hanke, and A. Fomsgaard (2003)
J. Gen. Virol. 84, 203-213
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products